ストックスクリーナーアプリを入手
13.44
0.37%
-0.05
アフターアワーズ：
13.55
0.11
+0.82%
前日終値:
$13.49
開ける：
$13.45
24時間の取引高:
1.04M
Relative Volume:
0.67
時価総額：
$1.42B
収益：
-
当期純損益:
$-44.84M
株価収益率:
-28.60
EPS:
-0.47
ネットキャッシュフロー:
$-44.23M
1週間 パフォーマンス:
-7.05%
1か月 パフォーマンス:
+0.75%
6か月 パフォーマンス:
-21.13%
1年 パフォーマンス:
+52.73%
1日の値動き範囲:
$13.36
$14.00
1週間の範囲:
$13.06
$14.35
52週間の値動き範囲:
$7.55
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
名前
Ars Pharmaceuticals Inc
セクター
電話
858-771-9307
住所
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
13.44 | 1.42B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-10 | 開始されました | Oppenheimer | Outperform |
| 2024-08-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 繰り返されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | Raymond James | Outperform |
| 2024-03-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Wedbush | Outperform |
| 2023-01-03 | 開始されました | William Blair | Outperform |
| 2022-12-13 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
ARS Pharma’s epinephrine nasal spray 1mg now available in US - Yahoo
Neffy Maker Steps Up Awareness for MDs; Launches Kids’ Device - Allergic Living
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg - GlobeNewswire
ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website - marketscreener.com
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to - Stock Titan
Needle-Free Emergency Epinephrine Now Available for Pediatric Patients - Medical Professionals Reference
ARS Pharmaceuticals And 2 Other Growth Leaders With Insider Ownership - simplywall.st
(SPRY) Investment Analysis - news.stocktradersdaily.com
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - The Manila Times
ARS Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Expected on Anaphylaxis Treatment Progress - Stock Titan
ALK Abello inks neffy co-promotion deal in USA - The Pharma Letter
ARS Pharmaceuticals Partners with ALK for Neffy Promotion By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals Partners with ALK for Neffy Promotion - Investing.com Australia
ARS Pharmaceuticals Signs Co-Promotion Deal With ALK-Abello for Neffy Nasal Spray in US - marketscreener.com
ARS Pharma in pact with ALK-Abelló for neffy (SPRY:NASDAQ) - Seeking Alpha
ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S - marketscreener.com
ALK-Abello (AKBLF) Partners with ARS Pharma for Needle-Free Alle - GuruFocus
ALK enters into neffy® co-promotion agreement in the USA - The Manila Times
ARS Pharmaceuticals and ALK-Abelló A/S Expand Co-Promotion Agreement for neffy® Nasal Spray Ahead of Back-to-School Season - Nasdaq
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - GlobeNewswire
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ... - Eagle-Tribune
ARS Pharma Partners With ALK to Expand neffy Nasal Spray to 9,000 US Pediatricians | SPRY Stock News - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
ARS Pharmaceuticals Has A Blockbuster Candidate (NASDAQ:SPRY) - Seeking Alpha
(SPRY) On The My Stocks Page - news.stocktradersdaily.com
ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock By Investing.com - Investing.com India
ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock - Investing.com Australia
US High Growth Tech Stocks To Watch Now - Yahoo Finance
ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money - Insider Monkey
How the (SPRY) price action is used to our Advantage - news.stocktradersdaily.com
10 Unstoppable Stocks That Could Double Your Money - Insider Monkey
High Insider Ownership Growth Stocks To Know In April 2025 - simplywall.st
Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28% - simplywall.st
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Raymond James maintains Strong Buy on SPRY stock, $32 target - Investing.com
Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term - simplywall.st
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance
Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript - MSN
Raymond James lifts ARS Pharmaceuticals price target to $32 - Investing.com
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Pulmonology Advisor
ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - MSN
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock - Investing.com Australia
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock By Investing.com - Investing.com South Africa
Ars Pharmaceuticals Inc (SPRY) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):